References
- Phelan K, McDermid HE. The 22q13.3 Deletion Syndrome (Phelan-McDermid Syndrome). Mol Syndromol 2012;2:186-201.
- Phelan MC. Deletion 22q13.3 syndrome. Orphanet J Rare Dis 2008;3:14. https://doi.org/10.1186/1750-1172-3-14
- Guilmatre A, Huguet G, Delorme R, Bourgeron T. The emerging role of SHANK genes in neuropsychiatric disorders. Dev Neurobiol 2014;74:113-22. https://doi.org/10.1002/dneu.22128
- Sarasua SM, Boccuto L, Sharp JL, Dwivedi A, Chen CF, Rollins JD, et al. Clinical and genomic evaluation of 201 patients with Phelan-McDermid syndrome. Hum Genet 2014;133:847-59. https://doi.org/10.1007/s00439-014-1423-7
- Jacquemont ML, Sanlaville D, Redon R, Raoul O, Cormier-Daire V, Lyonnet S, et al. Array-based comparative genomic hybridisation identifies high frequency of cryptic chromosomal rearrangements in patients with syndromic autism spectrum disorders. J Med Genet 2006;43:843-9. https://doi.org/10.1136/jmg.2006.043166
- Na SR, Im BC, You JH, Cho HM, You EJ, Kim SJ, et al. A case of 22q13 deletion syndrome. J Korean Child Neurol Soc 2010;18:338-44. https://doi.org/10.26815/jkcns.2010.18.2.338
- Rollins JD, Sarasua SM, Phelan K, DuPont BR, Rogers RC, Collins JS. Growth in Phelan-McDermid syndrome. Am J Med Genet A 2011;155A:2324-6.
- Wilson HL, Wong AC, Shaw SR, Tse WY, Stapleton GA, Phelan MC, et al. Molecular characterisation of the 22q13 deletion syndrome supports the role of haploinsufficiency of SHANK3/PROSAP2 in the major neurological symptoms. J Med Genet 2003;40:575-84. https://doi.org/10.1136/jmg.40.8.575
- Boccuto L, Lauri M, Sarasua SM, Skinner CD, Buccella D, Dwivedi A, et al. Prevalence of SHANK3 variants in patients with different subtypes of autism spectrum disorders. Eur J Hum Genet 2013;21:310-6. https://doi.org/10.1038/ejhg.2012.175